| Bioactivity | PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability[1]. | ||||||||||||
| Invitro | PCC0208017 inhibits the activity of MARK3 and MARK4 and decreased the phosphorylation of Tau[1].PCC0208017 (1-5 μM; 24 hours) treatment results in decreased phosphorylation of Tau, the subtract of MARKs[1].PCC0208017 (3-21 μM; 24 hours) suppresses the proliferation of glioma cells[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | PCC0208017 | ||||||||||||
| CAS | 2623158-64-3 | ||||||||||||
| Formula | C19H20F3N7 | ||||||||||||
| Molar Mass | 403.40 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
PCC0208017
CAS: 2623158-64-3 F: C19H20F3N7 W: 403.40
PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respecti
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.